Lv11
90 积分 2025-10-09 加入
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies
8天前
已完结
Safety and pharmacokinetics of SOR102, an oral bispecific inhibitor of TNF and interleukin-23 in healthy participants and patients with ulcerative colitis: a first-in-human, double-blind, randomised, placebo-controlled, phase 1 trial
9天前
已完结
Safety and pharmacokinetics of SOR102, an oral bispecific inhibitor of TNF and interleukin-23 in healthy participants and patients with ulcerative colitis: a first-in-human, double-blind, randomised, placebo-controlled, phase 1 trial
9天前
已完结
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial
20天前
已完结
Risankizumab for Ulcerative Colitis
22天前
已完结
63262 Treatment patterns and effectiveness of Abrocitinib in atopic dermatitis: Interim analysis on real-world data in Abrocitinib Chinese rEgistry on AD (AHEAD)
1个月前
已完结
Are all the IL-23 blockers the same in inflammatory bowel disease?
1个月前
已完结
A comprehensive review of small molecules, targets, and pathways in ulcerative colitis treatment
1个月前
已完结
Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial
1个月前
已完结
IL-23 inhibition for chronic inflammatory disease
1个月前
已完结
皖公网安备34019202002308
